Study design and participation
diabetic, Diabetes
BLIND, DIABETES
This is a 3-month prospective double blind parallel randomized study, that involve 60 type 2 diabetic patients of both sexes recruited from outpatient clinics of Diabetes and Endocrinology Unit, Department of Internal Medicine, Tanta University hospitals, Tanta, Egypt. The study took place from January 2021 to February 2022. All the procedures were done according to standards ethical guidelines and were approved by the research and ethics committee of Damanhour University (No. 1219PP20). The trial was registered on clinical trial.gov by (NCT04240171). All the study subjects have agreed to take part in the trial and provided a written informed consent. The study participants were asked to keep the usual dietary and activity habits throughout the study period. Patients were randomly assigned to either dapagliflozin group (n = 30) or glimepiride group (n = 30) in 1:1 ratio manner. All the patients were on metformin 1000 mg daily for at least a year before the beginning of the study. The dapagliflozin group received dapagliflozin 10 mg daily in addition to their usual dose of metformin, while the glimepiride group received glimepiride 4 mg daily in addition to their usual dose of metformin.
